HHC
ALXN

Hutchin Hill Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Hutchin Hill Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,400
Closed -$1.26M – 1112
2017
Q1 		$1.26M Sell
10,400
-18,200
-64% -$2.35M 0.03% 430
2016
Q4 		$3.5M Buy
+28,600
New +$3.5M 0.12% 220
2015
Q1 		– Sell
-9,400
Closed -$1.74M – 832
2014
Q4 		$1.74M Buy
9,400
+3,000
+47% +$556K 0.06% 266
2014
Q3 		$1.06M Sell
6,400
-16,100
-72% -$2.64M 0.04% 358
2014
Q2 		$3.52M Sell
22,500
-2,500
-10% -$395K 0.16% 95
2014
Q1 		$3.8M Sell
25,000
-36,250
-59% -$5.76M 0.2% 82
2013
Q4 		$8.14M Buy
61,250
+17,250
+39% +$2.07M 0.56% 41
2013
Q3 		$5.11M Buy
44,000
+26,700
+154% +$2.93M 0.46% 47
2013
Q2 		$1.6M Buy
+17,300
New +$1.67M 0.16% 91

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hutchin Hill Capital's ALXN Position: Q2 2017 in Review

Hutchin Hill Capital sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 10,400 shares — an estimated $1.26M sold.

Hutchin Hill Capital first reported a position in ALXN in Q2 2013 and held it in 9 quarters. The position peaked at $8.14M in Q4 2013. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Hutchin Hill Capital reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 10,400 Alexion Pharmaceuticals shares in Q2 2017, an estimated $1.26M.
  • Hutchin Hill Capital first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • Hutchin Hill Capital's Alexion Pharmaceuticals position peaked at $8.14M in Q4 2013.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Hutchin Hill Capital's 13F filing for Q2 2017, filed 14 Aug 2017.